13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001587114
Total reported value
$2.1B
$2.1B
30 檔
61.7%
During the Q3 2025 filing period, EcoR1 Capital, LLC (CIK: 0001587114) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $2.1B across 30 reported positions.
In Q3 2025, EcoR1 Capital, LLC adopted a defensive or profit-taking posture, trimming 4 positions and completely liquidating 20 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ZYME | Zymeworks Inc | Stock-Other | 18.83% | +4.78% | — | |
| 2 | ANAB | Anaptysbio Inc | Stock-Other | 11.58% | +7.31% | — | |
| 3 | QURE | uniQure N.V. | Stock-Other | 11.17% | — | -3.27% | |
| 4 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 10.79% | -13.69% | EXIT | |
| 5 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 8.57% | -6.61% | EXIT | |
| 6 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 4.32% | +0.88% | — | |
| 7 | TNGX | Tango Therapeutics Inc | Stock-Other | 4.29% | — | — | |
| 8 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 3.87% | -0.08% | +315.81% | |
| 9 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 3.74% | — | -71.02% | |
| 10 | XNCR | Xencor Inc | Stock-Other | 3.46% | -1.12% | EXIT | |
| 11 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 2.77% | +0.31% | +60.77% | |
| 12 | IMNM | Immunome Inc | Stock-Other | 2.29% | — | — | |
| 13 | ETON | Eton Pharmaceuticals Inc | Stock-Other | 2.12% | +1.55% | — | |
| 14 | MBX | Mbx Biosciences Inc | Stock-Other | 1.78% | +0.06% | +84.69% | |
| 15 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.65% | — | — | |
| 16 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 1.60% | — | +53.00% | |
| 17 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 1.57% | -0.02% | — | |
| 18 | NGNE | Neurogene Inc | Stock-Other | 1.06% | +0.85% | — | |
| 19 | ALKS | Alkermes plc | Stock-Healthcare | 0.72% | — | — | |
| 20 | AQST | Aquestive Therapeutics Inc | Stock-Other | 0.70% | — | — | |
| 21 | ✓ | Stock-Other | 0.68% | — | — | ||
| 22 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.64% | -10.81% | EXIT | |
| 23 | PRME | Prime Medicine Inc | Stock-Other | 0.41% | — | — | |
| 24 | ATRA | Atara Biotherapeutics Inc | Stock-Other | 0.39% | +0.85% | — | |
| 25 | KURA | Kura Oncology Inc | Stock-Other | 0.37% | — | -79.23% | |
| 26 | PEPG | Pepgen Inc | Stock-Other | 0.18% | — | — | |
| 27 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.17% | — | — | |
| 28 | VYGR | Voyager Therapeutics Inc | Stock-Other | 0.15% | — | -82.89% | |
| 29 | CMPS | Compass Pathways PLC | Stock-Other | 0.07% | — | — | |
| 30 | SRZNW | Surrozen Inc-cw25 | Stock-Other | 0.04% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | QURE | uniQure N.V. | +8.6% | -3.27% | Trim |
| 2 | ZYME | Zymeworks Inc | +6.6% | — | Add |
| 3 | TNGX | Tango Therapeutics Inc | +3.4% | — | Unchanged |
| 4 | ANAB | Anaptysbio Inc | +2.9% | — | Unchanged |
| 5 | ORIC | Oric Pharmaceuticals Inc | +2.7% | +315.81% | Add |
| 6 | LKFT | Lakefront Biotherapeutic-adr | +2.5% | +60.77% | Add |
| 7 | CRSP | CRISPR Therapeutics AG | +1.5% | — | Unchanged |
| 8 | MBX | Mbx Biosciences Inc | +1.2% | +84.69% | Add |
| 9 | IMNM | Immunome Inc | +0.7% | — | Unchanged |
| 10 | RNAGBP | Avidity Biosciences Inc | +0.6% | +53.00% | Add |
| 11 | ✓ | +0.6% | — | Add | |
| 12 | ETON | Eton Pharmaceuticals Inc | +0.6% | — | Add |
| 13 | PRME | Prime Medicine Inc | +0.3% | — | Add |
| 14 | ATRA | Atara Biotherapeutics Inc | +0.2% | — | Unchanged |
| 15 | MDGL | Madrigal Pharmaceuticals Inc | +0.2% | — | Unchanged |
| 16 | NGNE | Neurogene Inc | +0.2% | — | Unchanged |
| 17 | NUVB-WS | Nuvation Bio Inc -cw27 | +0.1% | — | Unchanged |
| 18 | CRNX | Crinetics Pharmaceuticals In | 0% | — | Unchanged |
| 19 | SRZNW | Surrozen Inc-cw25 | 0% | — | Unchanged |
| 20 | XNCR | Xencor Inc | -0.4% | — | Unchanged |
| 21 | VYGR | Voyager Therapeutics Inc | -0.6% | -82.89% | Trim |
| 22 | KURA | Kura Oncology Inc | -0.7% | -79.23% | Trim |
| 23 | JAZZ | Jazz Pharmaceuticals plc | -1.8% | — | Unchanged |
| 24 | APLSUSD | Apellis Pharmaceuticals Inc | -11.7% | -71.02% | Trim |
| 25 | PRTA | Prothena Corporation plc | — | EXIT | Sold out |
| 26 | SRPT | Sarepta Therapeutics Inc | — | EXIT | Sold out |
| 27 | JANX | Janux Therapeutics Inc | — | EXIT | Sold out |
| 28 | BBOT | Bridgebio Oncology Therapeut | — | NEW | New buy |
| 29 | AKRO | Akero Therapeutics Inc | — | EXIT | Sold out |
| 30 | TECX | Tectonic Therapeutic Inc | — | EXIT | Sold out |
| 31 | ALKS | Alkermes plc | — | NEW | New buy |
| 32 | AQST | Aquestive Therapeutics Inc | — | NEW | New buy |
| 33 | 260 | Centessa Pharmaceuticals-adr | — | NEW | New buy |
| 34 | BEAM | Beam Therapeutics Inc | — | EXIT | Sold out |
| 35 | DNA | Ginkgo Bioworks Holdings Inc | — | EXIT | Sold out |
| 36 | REPL | Replimune Group Inc | — | EXIT | Sold out |
| 37 | BCYC | Bicycle Therapeutics Plc-adr | — | EXIT | Sold out |
| 38 | DAWNGBX | Day One Biopharmaceuticals I | — | EXIT | Sold out |
| 39 | ✓ | Verve Therapeutics Inc | — | EXIT | Sold out |
| 40 | ADAPY | Adaptimmune Therapeutics-adr | — | EXIT | Sold out |
| 41 | WHWK | Whitehawk Therapeutics Inc | — | EXIT | Sold out |
| 42 | PEPG | Pepgen Inc | — | NEW | New buy |
| 43 | SLDB | Solid Biosciences Inc | — | EXIT | Sold out |
| 44 | KROS | Keros Therapeutics Inc | — | EXIT | Sold out |
| 45 | RLAY | Relay Therapeutics Inc | — | EXIT | Sold out |
| 46 | KLRS | Kalaris Therapeutics Inc | — | EXIT | Sold out |
| 47 | CMPS | Compass Pathways PLC | — | NEW | New buy |
| 48 | TCRX | Tscan Therapeutics Inc | — | EXIT | Sold out |
| 49 | ALGS | Aligos Therapeutics Inc | — | EXIT | Sold out |
| 50 | UPB | Upstream Bio Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, EcoR1 Capital, LLC reported a total U.S. public equity portfolio value of $2.1B across 30 disclosed positions in Q3 2025.
During Q3 2025, EcoR1 Capital, LLC's top holdings by market value included ZYME (18.8%)、ANAB (11.6%)、QURE (11.2%). The largest single position, ZYME, represented 18.8% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ZYME, ANAB, QURE) accounted for 61.7% of total reported equity market value during Q3 2025.
Top New Position Initiated
BBOT
市值: $32.7M
Top Position Liquidated / Trimmed
PRTA
前期市值: $143.4M
In Q3 2025, EcoR1 Capital, LLC made 38 total portfolio adjustments, initiating 6 new buys, adding to 8 positions, trimming 4 holdings, and fully liquidating 20 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.